JP5697679B2 - Ｃ型肝炎ウイルス阻害剤 - Google Patents
Ｃ型肝炎ウイルス阻害剤 Download PDFInfo
- Publication number
- JP5697679B2 JP5697679B2 JP2012538923A JP2012538923A JP5697679B2 JP 5697679 B2 JP5697679 B2 JP 5697679B2 JP 2012538923 A JP2012538923 A JP 2012538923A JP 2012538923 A JP2012538923 A JP 2012538923A JP 5697679 B2 JP5697679 B2 JP 5697679B2
- Authority
- JP
- Japan
- Prior art keywords
- imidazol
- pyrrolidinyl
- solvent
- methyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Cc1c(B*c2c(*)[n]c(*)n2)nc(C2N(*)CCC2)[n]1 Chemical compound Cc1c(B*c2c(*)[n]c(*)n2)nc(C2N(*)CCC2)[n]1 0.000 description 7
- YENRRSJOGNVHLX-OVRZELKPSA-N C/C=C\C(\F)=C(\CC(O)=O)/C=C Chemical compound C/C=C\C(\F)=C(\CC(O)=O)/C=C YENRRSJOGNVHLX-OVRZELKPSA-N 0.000 description 1
- MHQZDNQHLGFBRN-UHFFFAOYSA-N C=Cc1c[nH]cn1 Chemical compound C=Cc1c[nH]cn1 MHQZDNQHLGFBRN-UHFFFAOYSA-N 0.000 description 1
- ARVYNIUWNHGVMK-UHFFFAOYSA-N CC(C)(C1)OCCC1C(C(O)=O)NC(OC)=O Chemical compound CC(C)(C1)OCCC1C(C(O)=O)NC(OC)=O ARVYNIUWNHGVMK-UHFFFAOYSA-N 0.000 description 1
- FMWXPWOCDITRKF-UHFFFAOYSA-N CC1C(OCc2ccccc2)=[O]=[I]C1(C1)C23C1OC2CC3 Chemical compound CC1C(OCc2ccccc2)=[O]=[I]C1(C1)C23C1OC2CC3 FMWXPWOCDITRKF-UHFFFAOYSA-N 0.000 description 1
- ZWVBAHITHMYEMS-SECBINFHSA-N CCNC(N[C@@H](C(O)=O)c1ccccc1)=O Chemical compound CCNC(N[C@@H](C(O)=O)c1ccccc1)=O ZWVBAHITHMYEMS-SECBINFHSA-N 0.000 description 1
- JCWUTEGWHABTTF-VIFPVBQESA-N CN(C)[C@H](C(O)=O)c(cccc1)c1F Chemical compound CN(C)[C@H](C(O)=O)c(cccc1)c1F JCWUTEGWHABTTF-VIFPVBQESA-N 0.000 description 1
- OZKZHAPLKMRAQT-UHFFFAOYSA-N CN(CC(O)=O)Cc1ccccc1 Chemical compound CN(CC(O)=O)Cc1ccccc1 OZKZHAPLKMRAQT-UHFFFAOYSA-N 0.000 description 1
- OQZOPIFSTNJPIM-UHFFFAOYSA-N CN(CC1)CCN1C(C(O)=O)c1ccccc1 Chemical compound CN(CC1)CCN1C(C(O)=O)c1ccccc1 OQZOPIFSTNJPIM-UHFFFAOYSA-N 0.000 description 1
- CWLQUGTUXBXTLF-RXMQYKEDSA-N CN(CCC1)[C@H]1C(O)=O Chemical compound CN(CCC1)[C@H]1C(O)=O CWLQUGTUXBXTLF-RXMQYKEDSA-N 0.000 description 1
- ZUOXHVHNWWEXSD-XYOKQWHBSA-N COC(/N=C/C(CCN1CCOCC1)C(O)=O)=O Chemical compound COC(/N=C/C(CCN1CCOCC1)C(O)=O)=O ZUOXHVHNWWEXSD-XYOKQWHBSA-N 0.000 description 1
- JSWJZHLINSQJSP-UHFFFAOYSA-N COC(NC(C1C2COCC1CC2)C(O)=O)=O Chemical compound COC(NC(C1C2COCC1CC2)C(O)=O)=O JSWJZHLINSQJSP-UHFFFAOYSA-N 0.000 description 1
- KURWVNFJNNCXOE-SECBINFHSA-N COC(N[C@@H](C(O)=O)C(C=CCC=C1)=C1Cl)=O Chemical compound COC(N[C@@H](C(O)=O)C(C=CCC=C1)=C1Cl)=O KURWVNFJNNCXOE-SECBINFHSA-N 0.000 description 1
- GOJLQSAREKTKPT-MRVPVSSYSA-N COC(N[C@@H](C(O)=O)c1ccccc1)=O Chemical compound COC(N[C@@H](C(O)=O)c1ccccc1)=O GOJLQSAREKTKPT-MRVPVSSYSA-N 0.000 description 1
- VBQNMJLWFTYJQQ-PRZNWYJVSA-N COC(N[C@@H](C1(C2)C2OCCC1)C(O)=O)=O Chemical compound COC(N[C@@H](C1(C2)C2OCCC1)C(O)=O)=O VBQNMJLWFTYJQQ-PRZNWYJVSA-N 0.000 description 1
- ZHYQQMPGESIRRQ-ASLNEKEESA-N COC(N[C@@H]([C@@H]1COCCC1)C(O)=O)O Chemical compound COC(N[C@@H]([C@@H]1COCCC1)C(O)=O)O ZHYQQMPGESIRRQ-ASLNEKEESA-N 0.000 description 1
- GHAQIXXBUHNFHR-YUMQZZPRSA-N COC([C@H]([C@@H]1COCCC1)NC(OC)=O)=O Chemical compound COC([C@H]([C@@H]1COCCC1)NC(OC)=O)=O GHAQIXXBUHNFHR-YUMQZZPRSA-N 0.000 description 1
- DYTJEQBUSOPLJD-NTSWFWBYSA-N CO[C@H](CC1)C[C@H]1O Chemical compound CO[C@H](CC1)C[C@H]1O DYTJEQBUSOPLJD-NTSWFWBYSA-N 0.000 description 1
- IYRQAHMILBSLLI-LURJTMIESA-N C[C@@H](C(N1CCCC1)=O)I Chemical compound C[C@@H](C(N1CCCC1)=O)I IYRQAHMILBSLLI-LURJTMIESA-N 0.000 description 1
- PKSHBKQBIJCPDK-LURJTMIESA-N C[C@@H](CC(C1)=O)OC1=C Chemical compound C[C@@H](CC(C1)=O)OC1=C PKSHBKQBIJCPDK-LURJTMIESA-N 0.000 description 1
- ORVYPIPXACDBMU-CRCLSJGQSA-N C[C@@H]([C@@H](C)O)NC(OC)=O Chemical compound C[C@@H]([C@@H](C)O)NC(OC)=O ORVYPIPXACDBMU-CRCLSJGQSA-N 0.000 description 1
- QSGQRCSPXYYLGN-LBPRGKRZSA-N C[C@@H](c1ccccc1)OC(Cc1ccccc1F)=O Chemical compound C[C@@H](c1ccccc1)OC(Cc1ccccc1F)=O QSGQRCSPXYYLGN-LBPRGKRZSA-N 0.000 description 1
- KMAYERAFUKKXME-KSSFIOAISA-N C[C@@H](c1ccccc1)OC([C@H](c(cccc1)c1[I]=C)N(C)C)=O Chemical compound C[C@@H](c1ccccc1)OC([C@H](c(cccc1)c1[I]=C)N(C)C)=O KMAYERAFUKKXME-KSSFIOAISA-N 0.000 description 1
- LGOUUMRFIYBPDO-PSASIEDQSA-N C[C@H](CN)C1=C(C)CC[C@@H](C)C1 Chemical compound C[C@H](CN)C1=C(C)CC[C@@H](C)C1 LGOUUMRFIYBPDO-PSASIEDQSA-N 0.000 description 1
- PXHHIBMOFPCBJQ-ZCFIWIBFSA-N C[C@H]1N(C)CCC1 Chemical compound C[C@H]1N(C)CCC1 PXHHIBMOFPCBJQ-ZCFIWIBFSA-N 0.000 description 1
- LMIZLNPFTRQPSF-SSDOTTSWSA-N N[C@@H](C(O)=O)c(cccc1)c1Cl Chemical compound N[C@@H](C(O)=O)c(cccc1)c1Cl LMIZLNPFTRQPSF-SSDOTTSWSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N N[C@@H](C(O)=O)c1ccccc1 Chemical compound N[C@@H](C(O)=O)c1ccccc1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 1
- ALMBVNDWQWJTNP-JPYDVTDNSA-N O=C([C@@H](c1ccccc1)N1CCCCC1)N(CCC1)[C@@H]1c1ncc(C#CC#Cc2cnc([C@H](CCC3)N3C([C@@H](c3ccccc3)N3CCCCC3)=O)[nH]2)[nH]1 Chemical compound O=C([C@@H](c1ccccc1)N1CCCCC1)N(CCC1)[C@@H]1c1ncc(C#CC#Cc2cnc([C@H](CCC3)N3C([C@@H](c3ccccc3)N3CCCCC3)=O)[nH]2)[nH]1 ALMBVNDWQWJTNP-JPYDVTDNSA-N 0.000 description 1
- KGSVNOLLROCJQM-UHFFFAOYSA-N OC(CNCc1ccccc1)=O Chemical compound OC(CNCc1ccccc1)=O KGSVNOLLROCJQM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26056909P | 2009-11-12 | 2009-11-12 | |
| US61/260,569 | 2009-11-12 | ||
| US12/942,183 | 2010-11-09 | ||
| US12/942,183 US20110281910A1 (en) | 2009-11-12 | 2010-11-09 | Hepatitis C Virus Inhibitors |
| PCT/US2010/056114 WO2011060000A1 (en) | 2009-11-12 | 2010-11-10 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013510857A JP2013510857A (ja) | 2013-03-28 |
| JP2013510857A5 JP2013510857A5 (https=) | 2013-12-05 |
| JP5697679B2 true JP5697679B2 (ja) | 2015-04-08 |
Family
ID=43334735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538923A Expired - Fee Related JP5697679B2 (ja) | 2009-11-12 | 2010-11-10 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20110281910A1 (https=) |
| EP (1) | EP2499132B1 (https=) |
| JP (1) | JP5697679B2 (https=) |
| CN (1) | CN102712628B (https=) |
| WO (1) | WO2011060000A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| US8546405B2 (en) | 2008-12-23 | 2013-10-01 | Abbott Laboratories | Anti-viral compounds |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9278922B2 (en) * | 2009-04-15 | 2016-03-08 | Abbvie Inc. | Anti-viral compounds |
| HUE030465T2 (hu) | 2009-05-13 | 2017-05-29 | Antivirális vegyületek | |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| EA020031B1 (ru) | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102869657A (zh) | 2010-03-24 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 用于治疗或预防黄病毒感染的类似物 |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| RU2452735C1 (ru) * | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
| WO2012087976A2 (en) * | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US8552047B2 (en) * | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| CN105837561B (zh) * | 2013-06-06 | 2019-06-28 | 上海爱博医药科技有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| PT3038601T (pt) | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN105985356B (zh) * | 2015-02-05 | 2018-06-22 | 四川大学 | 咪唑[2,1-b]噻唑衍生物及其制备方法和用途 |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| GB2552919A (en) * | 2015-11-18 | 2018-02-21 | Azad Pharmaceutical Ingredients Ag | Stable amorphous form of daclatasvir |
| US12037340B2 (en) | 2021-05-21 | 2024-07-16 | Gilead Sciences, Inc. | Pentacyclic derivatives as Zika virus inhibitors |
| US12497408B2 (en) | 2021-05-21 | 2025-12-16 | Gilead Sciences, Inc. | Tetracyclic compounds and methods for the treatment of Zika virus infection |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654451B1 (en) | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
| JPH08505854A (ja) | 1993-01-14 | 1996-06-25 | マガイニン ファーマシューティカルズ，インク． | 修飾された末端を有するアミノ酸及びペプチド |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| AU2003249977A1 (en) | 2002-07-05 | 2004-01-23 | Axxima Pharmaceuticals Ag | Imidazole compounds for the treatment of hepatitis c virus infections |
| AU2003264038A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Combination pharmaceutical agents as inhibitors of hcv replication |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE102004036971B4 (de) | 2004-07-30 | 2009-07-30 | Advanced Micro Devices, Inc., Sunnyvale | Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| WO2006093867A1 (en) | 2005-02-28 | 2006-09-08 | The Rockefeller University | Structure of the hepatitits c virus ns5a protein |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| EP1940786B1 (en) | 2005-09-16 | 2010-08-18 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
| WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
| US7910595B2 (en) | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| KR20090012345A (ko) | 2006-05-30 | 2009-02-03 | 애로우 쎄라퓨틱스 리미티드 | 바이페닐 유도체, 및 ｃ형 간염 치료에 있어서의 이들의 용도 |
| ES2745411T3 (es) | 2006-07-27 | 2020-03-02 | Wang Nai Fang | Compuestos y composiciones de arilsulfanilo para administración de agentes activos |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN101558059B (zh) * | 2006-08-11 | 2014-12-03 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| JP2010510245A (ja) | 2006-11-21 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | 抗ウイルス化合物 |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| KR20100123717A (ko) | 2008-02-12 | 2010-11-24 | 브리스톨-마이어스 스큅 컴퍼니 | Ｃ형 간염 바이러스 억제제로서의 헤테로시클릭 유도체 |
| DK2250163T3 (da) | 2008-02-12 | 2012-07-16 | Bristol Myers Squibb Co | Hepatitis C-virusinhibitorer |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2009102325A1 (en) | 2008-02-13 | 2009-08-20 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| CA2750577A1 (en) * | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| WO2010065674A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| EP2393359A4 (en) | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | COMPOUND DIBENZIMIDAZOLE DERIVATIVES |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| WO2010096462A1 (en) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| US20120040977A1 (en) | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| RU2544010C2 (ru) | 2009-02-27 | 2015-03-10 | Энанта Фармасьютикалс, Инк. | Ингибиторы вируса гепатита с |
| SG174883A1 (en) | 2009-03-27 | 2011-11-28 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c |
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| DK2410844T3 (en) | 2009-03-27 | 2016-07-04 | Merck Sharp & Dohme | Inhibitors of hepatitis C virus replication |
| US20110237636A1 (en) | 2009-03-30 | 2011-09-29 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| TWI476190B (zh) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9278922B2 (en) | 2009-04-15 | 2016-03-08 | Abbvie Inc. | Anti-viral compounds |
| MX2011011136A (es) | 2009-04-24 | 2011-11-18 | Tibotec Pharm Ltd | Eteres diarilicos. |
| EP2430015B1 (en) | 2009-05-12 | 2015-06-17 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds useful for the treatment of viral diseases |
| HUE030465T2 (hu) * | 2009-05-13 | 2017-05-29 | Antivirális vegyületek | |
| JP2012528195A (ja) | 2009-05-29 | 2012-11-12 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物 |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2435421A1 (en) | 2009-05-29 | 2012-04-04 | Schering Corporation | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA020031B1 (ru) | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
| WO2011015657A1 (en) | 2009-08-07 | 2011-02-10 | Tibotec Pharmaceuticals | Phenyl ethynyl derivatives as hepatitis c virus inhibitors |
| WO2011015658A1 (en) | 2009-08-07 | 2011-02-10 | Tibotec Pharmaceuticals | Bis-benzimidazole derivatives as hepatitis c virus inhibitors |
| AU2010291215A1 (en) | 2009-09-03 | 2012-02-23 | Janssen Sciences Ireland Uc | Bis-benzimidazole derivatives |
| CN102480971B (zh) | 2009-09-04 | 2014-11-26 | 杨森制药公司 | 化合物 |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011031934A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| WO2011050146A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| TWI429645B (en) | 2009-12-04 | 2014-03-11 | Proline derivatives | |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2012006877A (es) | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
| US20110152246A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| AU2010341537A1 (en) | 2009-12-22 | 2012-08-09 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases |
| MX2012007420A (es) | 2009-12-24 | 2012-07-23 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones de flavivirus. |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| PE20130244A1 (es) | 2010-01-25 | 2013-03-10 | Enanta Pharm Inc | Inhibidores del virus de la hepatitis c |
| JP2013518062A (ja) | 2010-01-28 | 2013-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎阻害化合物 |
| US20120196794A1 (en) | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
-
2010
- 2010-11-09 US US12/942,183 patent/US20110281910A1/en not_active Abandoned
- 2010-11-10 EP EP10779401.8A patent/EP2499132B1/en not_active Not-in-force
- 2010-11-10 WO PCT/US2010/056114 patent/WO2011060000A1/en not_active Ceased
- 2010-11-10 CN CN201080061374.4A patent/CN102712628B/zh not_active Expired - Fee Related
- 2010-11-10 JP JP2012538923A patent/JP5697679B2/ja not_active Expired - Fee Related
-
2012
- 2012-09-12 US US13/611,708 patent/US8618153B2/en active Active
-
2013
- 2013-09-16 US US14/027,531 patent/US20140018389A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130012540A1 (en) | 2013-01-10 |
| EP2499132B1 (en) | 2017-02-15 |
| CN102712628B (zh) | 2014-10-15 |
| JP2013510857A (ja) | 2013-03-28 |
| CN102712628A (zh) | 2012-10-03 |
| US20140018389A1 (en) | 2014-01-16 |
| US8618153B2 (en) | 2013-12-31 |
| US20110281910A1 (en) | 2011-11-17 |
| EP2499132A1 (en) | 2012-09-19 |
| WO2011060000A1 (en) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5697679B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5612661B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5612660B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5615352B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5847284B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5558557B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5785189B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5611959B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5632910B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5612612B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5599792B2 (ja) | Ｃ型肝炎ウイルス阻害剤としてのｂｉ−１ｈ−ベンズアミダゾール | |
| JP5619289B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| TWI475019B (zh) | Ｃ型肝炎病毒抑制劑 | |
| JP5558556B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5425815B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5596861B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5455933B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2010527373A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2011511832A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2011511841A (ja) | Ｃ型肝炎ウイルス阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131015 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131015 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140918 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141209 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150113 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150210 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5697679 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |